Business Wire

World Leaders and Industry Icons Unite Under BRIDGE Alliance to Empower the Future of Media, Entertainment and Content

12.11.2025 14:11:00 CET | Business Wire | Press Release

Share

A new international alliance of policymakers, creative leaders, and innovators has come together under the banner of BRIDGE Alliance to advance inclusivity, investment, and sustainable development in the global media, entertainment and content economy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112707768/en/

World leaders and industry icons unite under BRIDGE Alliance to empower the future of media, entertainment and content (Photo: AETOSWire)

Headquartered in the UAE, BRIDGE Alliance stands as a first-of-its-kind global body chaired by H.E. Abdulla bin Mohammed bin Butti Al Hamed. It brings together an influential board comprising former heads of state, global leaders, policymakers, and CEOs from the media, communication, technology, finance, and creative sectors.

The founding board includes HRH Princess Lamia bint Majed Al Saud, CEO of Rotana Media Group and Secretary-General of Alwaleed Philanthropies; H.E. Macky Sall, fourth President of Senegal; H.E. Dr. Jamal Mohammed Obaid Al Kaabi, Vice-Chairman of BRIDGE Alliance; Jessica Sibley, CEO of TIME; Janet Yang, former President of the Academy of Motion Picture Arts and Sciences; Dr. Julie Gichuru, CEO of the Africa Leadership and Dialogue Institute; Daniil Shuleyko, CEO of Yango Group; Sanford Climan, Founder of Entertainment Media Ventures; strategist Richard Attias; and Maryam bin Fahad, Managing Director of BRIDGE Alliance.

Operating as an independent, mission-driven organization, BRIDGE Alliance reinvests all operational surpluses into advancing research, capacity building, and innovation. It aims to enhance cooperation, enabling ideas, capital, and talent to move more effectively across target sectors.

H.E. Al Hamed described the Alliance as “a humanitarian and economic project born in the UAE to redefine the relationship between media, society, and the economy — building bridges of understanding, impact, and growth among nations.” He added that BRIDGE “embodies a global ecosystem founded on collaboration, innovation, and shared responsibility, where expertise turns ideas into impact and partnerships into progress.”

The Alliance’s first major initiative, BRIDGE Summit 2025, will take place from December 8–10 at the Abu Dhabi National Exhibition Center (ADNEC). The world’s largest debut media event, it will convene 60,000 participants, 400 speakers, and 300 exhibitors across seven tracks — Media, Creator Economy, Music, Gaming, Technology, Marketing, and Picture — turning dialogue into action and expanding access to the global content economy.

From its base in the UAE, BRIDGE Alliance is a global hub for innovation, collaboration, and responsible media growth — reinforcing the nation’s role as a meeting point for ideas, creativity, and shared progress.

Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20251112707768/en/

Contacts

Natalie Habib
n.habib@nncpr.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye